← Back to patent-cliff list
Lutetium (177Lu) vipivotide tetraxetan
Tier C — Watch / tradeLutetium (177Lu) vipivotide tetraxetan
Radiomedix Inc
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PSMA
Brand：PLUVICTO
Indications (approved)：Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Prostate cancer
Regional status
US
Approved
2022-03-23
EU
Approved
2022-12-09
China
Approved
2025-11-04
Japan
Approved
2025-09-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lutetium (177Lu) vipivotide tetraxetan?
Approved indications include: Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Prostate cancer.
When does the Lutetium (177Lu) vipivotide tetraxetan patent expire?
No public expiry year is available for Lutetium (177Lu) vipivotide tetraxetan yet; this page updates once verified.
How do I get a quote for Lutetium (177Lu) vipivotide tetraxetan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01